Limits...
Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy

View Article: PubMed Central - PubMed

ABSTRACT

Lipocalin 2 (LCN2) is a secreted protein that belongs to the Lipocalins, a group of transporters of small lipophilic molecules such as steroids, lipopolysaccharides, iron, and fatty acids in circulation. Two decades after its discovery and after a high variety of published findings, LCN2's altered expression has been assigned to critical roles in several pathological organ conditions, including liver injury and steatosis, renal damage, brain injury, cardiomyopathies, muscle-skeletal disorders, lung infection, and cancer in several organs. The significance of this 25-kDa lipocalin molecule has been impressively increased during the last years. Data from several studies indicate the role of LCN2 in physiological conditions as well as in response to cellular stress and injury. LCN2 in the liver shows a protective role in acute and chronic injury models where its expression is highly elevated. Moreover, LCN2 expression is being considered as a potential strong biomarker for pathological conditions, including rheumatic diseases, cancer in human organs, hepatic steatosis, hepatic damage, and inflammation. In this review, we summarize experimental and clinical findings linking LCN2 to the pathogenesis of liver disease.

No MeSH data available.


Related in: MedlinePlus

LCN2 in the pathogenesis of liver diseases. LCN2 is a versatile adiponectin that influences all kinds of liver diseases. For more details on experimental and clinical findings associated with altered LCN2 expression refer to Table 3.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5037186&req=5

Figure 3: LCN2 in the pathogenesis of liver diseases. LCN2 is a versatile adiponectin that influences all kinds of liver diseases. For more details on experimental and clinical findings associated with altered LCN2 expression refer to Table 3.

Mentions: During the last years, LCN2 has been studied widely as a possible non-invasive biomarker for several organ disorders, as outlined above. Hepatic expression of LCN2 in disease is the most intensively studied chapter with almost 1/4 of the published findings targeting the roles of LCN2 in liver homeostasis. The liver is the vital organ for fat and carbohydrate metabolism. It is the body's production facility for many metabolites, hormones, and proteins that also detoxifies substances and excretes metabolites. Thus, any functional impairment in liver affects undesirably the whole organism. Experimental and clinical findings indicating altered hepatic LCN2 expression in numerous disease conditions are given in Figure 3 whereas the most recent findings are gathered in Table 3.


Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy
LCN2 in the pathogenesis of liver diseases. LCN2 is a versatile adiponectin that influences all kinds of liver diseases. For more details on experimental and clinical findings associated with altered LCN2 expression refer to Table 3.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5037186&req=5

Figure 3: LCN2 in the pathogenesis of liver diseases. LCN2 is a versatile adiponectin that influences all kinds of liver diseases. For more details on experimental and clinical findings associated with altered LCN2 expression refer to Table 3.
Mentions: During the last years, LCN2 has been studied widely as a possible non-invasive biomarker for several organ disorders, as outlined above. Hepatic expression of LCN2 in disease is the most intensively studied chapter with almost 1/4 of the published findings targeting the roles of LCN2 in liver homeostasis. The liver is the vital organ for fat and carbohydrate metabolism. It is the body's production facility for many metabolites, hormones, and proteins that also detoxifies substances and excretes metabolites. Thus, any functional impairment in liver affects undesirably the whole organism. Experimental and clinical findings indicating altered hepatic LCN2 expression in numerous disease conditions are given in Figure 3 whereas the most recent findings are gathered in Table 3.

View Article: PubMed Central - PubMed

ABSTRACT

Lipocalin 2 (LCN2) is a secreted protein that belongs to the Lipocalins, a group of transporters of small lipophilic molecules such as steroids, lipopolysaccharides, iron, and fatty acids in circulation. Two decades after its discovery and after a high variety of published findings, LCN2's altered expression has been assigned to critical roles in several pathological organ conditions, including liver injury and steatosis, renal damage, brain injury, cardiomyopathies, muscle-skeletal disorders, lung infection, and cancer in several organs. The significance of this 25-kDa lipocalin molecule has been impressively increased during the last years. Data from several studies indicate the role of LCN2 in physiological conditions as well as in response to cellular stress and injury. LCN2 in the liver shows a protective role in acute and chronic injury models where its expression is highly elevated. Moreover, LCN2 expression is being considered as a potential strong biomarker for pathological conditions, including rheumatic diseases, cancer in human organs, hepatic steatosis, hepatic damage, and inflammation. In this review, we summarize experimental and clinical findings linking LCN2 to the pathogenesis of liver disease.

No MeSH data available.


Related in: MedlinePlus